Denali Therapeutics DNLI 深 沪
等待开盘 08-15 09:30:00 美东时间
14.46
-0.350
-2.36%
华盛通- 最 高14.69
- 今 开14.44
- 成交量 176.71万股
- 最 低 14.0421
- 昨 收 14.81
- 总市值 21.11亿
- 52周最高 33.33
- 市盈率 静 --
- 换手率 1.21%
- 52周最低 10.57
- 委 比 -99.91%
- 总股本 1.46亿
- 历史最高 93.94
- 量 比 0.88
- 振 幅 4.37%
- 历史最低 10.57
- 每 手 1
- 风险率 5.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
Denali's Form S-4 registration statement has been approved by the SEC, enabling the proposed business combination with Semnur. The extraordinary general meeting of Denali shareholders to vote on this transaction is scheduled for September 3, 2025. Upon completion, the combined entity will operate as Semnur Pharmaceuticals, Inc. Scilex Holding Company, the parent of Semnur, specializes in non-opioid pain management solutions and has a diverse port...
08-13 10:00
Denali Therapeutics Advances in Neurodegenerative Treatments
Denali Therapeutics ( ($DNLI) ) has released its Q2 earnings. Here is a breakdo...
08-12 14:50
Denali Therapeutics Q2 EPS $(0.72) Misses $(0.62) Estimate
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.62) by 15.57 percent. This is a 22.03 percent decrease over losses of $(0.59) per share
08-12 04:19
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Denali Therapeutics reported its Q2 2025 financial results and business updates, highlighting progress in its therapeutic development programs. Key milestones include the FDA's priority review of tividenofusp alfa's BLA for Hunter syndrome with a PDUFA target action date of January 5, 2026, and alignment with the FDA on an accelerated approval path for DNL126 for Sanfilippo syndrome type A. The company is preparing for commercial launch and advan...
08-11 20:01
Denali Therapeutics Announces FDA Acceptance, Priority Review of Biologics License Application For Tividenofusp Alfa For Hunter Syndrome; Sets PDUFA Date Of Jan. 5, 2026
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approvalTividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brainTividenofusp
07-07 20:03
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
Denali Therapeutics announced the FDA's acceptance of its BLA for tividenofusp alfa for Hunter syndrome, granted Priority Review with a PDUFA target date of January 5, 2026. Tividenofusp alfa, an investigational enzyme replacement therapy, is engineered to deliver the missing IDS enzyme across the blood-brain barrier to treat both neurological and physical symptoms of MPS II. The BLA submission is supported by data from the Phase 1/2 study in 47 ...
07-07 12:00
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.
05-17 01:32
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
